Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats

Pediatric Nephrology

Volumn 23, Issue 12, 2008, Pages 2185-2194

  Zhang, Wei ^a   Li, Qiu ^a,b   Wang, Lijia ^a   Yang, Xiqiang ^a  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Adriamycin; Glomerulosclerosis; Interleukin 1 beta; Nephrosis rats; Nuclear factor kappa B

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPID; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; NEPHRITIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; DOXORUBICIN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; KIDNEY; KIDNEY DISEASES; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SCLEROSIS; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 55649097759     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0933-8     Document Type: Article

References (28)

1. Segerer S, Nelson PJ, Schlondorff D (2000) Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11:152-176
2. Rubartelli A, Cozzolino F, Talio M, Sitia R (1990) A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J 9:1503-1510
3. Franzen R, Pautz A, Brautigam L, Geisslinger G, Pfeilschifter J, Huwiler A (2001) Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem 276:35382-35389
4. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
5. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92:2419-2425
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
7. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H (2003) HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18:265-272
8. Harris KP, Purkerson ML, Yates J, Klahr S (1990) Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15:16-23
9. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK (2004) Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286:F46-F57
10. Jasinska M, Owczarek J, Orszulak-Michalak D (2007) Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59:483-499
11. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G (2002) Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635-1645
12. Chen A, Sheu LF, Ho YS, Lin YF, Chou WY, Chou TC, Lee WH (1998) Experimental focal segmental glomerulosclerosis in mice. Nephron 78:440-452
13. Rodriguez-Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND (2005) Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 68:1041-1047
14. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z (2003) Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 64:565-571
15. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J (2006) Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26:562-570
16. Ye S, Mozayeni P, Gamburd M, Zhong H, Campese VM (2000) Interleukin-1beta and neurogenic control of blood pressure in normal rats and rats with chronic renal failure. Am J Physiol Heart Circ Physiol 279:H2786-H2796
17. Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2:556-560
18. Tesch GH, Yang N, Yu H, Lan HY, Foti R, Chadban SJ, Atkins RC, Nikolic-Paterson DJ (1997) Intrinsic renal cells are the major source of interleukin-1 beta synthesis in normal and diseased rat kidney. Nephrol Dial Transplant 12:1109-1115
19. Niemir ZI, Stein H, Dworacki G, Mundel P, Koehl N, Koch B, Autschbach F, Andrassy K, Ritz E, Waldherr R, Otto HF (1997) Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int 52:393-403
20. Timoshanko JR, Kitching AR, Iwakura Y, Holdsworth SR, Tipping PG (2004) Contributions of IL-1beta and IL-1alpha to crescentic glomerulonephritis in mice. J Am Soc Nephrol 15:910-918
21. Karkar AM, Koshino Y, Cashman SJ, Dash AC, Bonnefoy J, Meager A, Rees AJ (1992) Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol 90:312-318
22. Karkar AM, Tam FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, Meager A, Rees AJ (1995) Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 48:1738-1746
23. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071
24. Guijarro C, Egido J (2001) Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 59:415-424
25. Shibata S, Nagase M, Fujita T (2006) Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17:754-764
26. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188-4194
27. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ AKT-signaling pathway. J Am Soc Nephrol 16:1936-1947
28. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H (2002) Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17:798-802